The UK National Health Service (NHS) began a mass rollout of weight loss injections, specifically the drug Mounjaro, in June 2025. General practitioners (GPs) in England are now authorized to prescribe these injections to patients who meet strict eligibility criteria, prioritizing those with the greatest need. The rollout marks the first time these weight loss jabs have been available through the NHS at GP surgeries. However, shortly after the rollout, concerns emerged regarding the safety of these drugs. Hundreds of users reported serious side effects, including pancreatitis, with some cases being life-threatening. The Medicines and Healthcare Regulatory Agency (MHRA) and Genomics England have initiated a study to investigate these potential side effects, prompted by reports linking Mounjaro, along with other injections like Ozempic and Wegovy, to nearly 300 cases of pancreatitis and six deaths in the UK. Despite these concerns, the MHRA has stated that there is currently no data to warrant alarm. Looking ahead, there are discussions about expanding the availability of NHS weight loss jabs beyond GP surgeries to locations such as high streets and shopping centres to meet demand.